Work

Abstract 1160: Debio 1562M, a 2ndgeneration ADC targeting CD37, shows high potency against AML and MDS and safe toxicological profile for future clinical development

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-1160

Authors: Lisa Ivanschitz, Josée Hue-Perron, Alain Monjardet, Noemie Luong, Esthela Artiga, Karilyn T. Larkin, Leo Marx

Institutions: Debiopharm (Switzerland), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409691255

Cites:

Cited by:

Related to: 10